Search Results

You are looking at 1 - 10 of 31 items for :

  • "nonalcoholic fatty liver disease" x
Clear All
Open access

Jia Li, Yan Zhao, Caoxin Huang, Zheng Chen, Xiulin Shi, Long Li, Zhong Chen and Xuejun Li

Introduction Nonalcoholic fatty liver disease (NAFLD) has become an important public health problem because of its high prevalence with lifestyle improvements. Currently, the principal treatment for NAFLD is lifestyle modification by diet and

Open access

Silan Zheng, Meifeng Tong, Lianqin Dong, Chunmin Du, Xin Zheng, Liying Wang, Peiying Huang, Wei Liu, Mingzhu Lin and Changqin Liu

nonalcoholic fatty liver disease (NAFLD) ( 2 ). A growing body of clinical and experimental evidences suggest that PCOS and NAFLD share similar clinical presentations including dyslipidemia, hypertension, and glycemic dysregulation ( 3 ). NAFLD is one of the

Open access

Frederique Van de Velde, Marlies Bekaert, Anja Geerts, Anne Hoorens, Arsène-Hélène Batens, Samyah Shadid, Margriet Ouwens, Yves Van Nieuwenhove and Bruno Lapauw

Introduction An important complication of obesity is the development of nonalcoholic fatty liver disease (NAFLD), which covers a broad histological spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH), and can progress to

Open access

Rachel D C A Diniz, Renata M Souza, Roberto Salvatori, Alex Franca, Elenilde Gomes-Santos, Thiago O Ferrão, Carla R P Oliveira, João A M Santana, Francisco A Pereira, Rita A A Barbosa, Anita H O Souza, Rossana M C Pereira, Alécia A Oliveira-Santos, Allysson M P Silva, Francisco J Santana-Júnior, Eugênia H O Valença, Viviane C Campos and Manuel H Aguiar-Oliveira

Introduction Nonalcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome and is associated with very common conditions such as obesity, type 2 diabetes, hypertension, dyslipidemia, and atherosclerosis (1) . NAFLD includes

Open access

Karim Gariani, Geneviève Drifte, Irène Dunn-Siegrist, Jérôme Pugin and François R Jornayvaz

lipid alterations, and FGF21 is considered as a key regulator in glucose and lipid metabolism (1, 6, 7, 8, 11) . FGF21 plasma levels are increased in type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and dyslipidemia (35, 36, 37, 38

Open access

Aneta Gawlik, Michael Shmoish, Michaela F Hartmann, Stefan A Wudy, Zbigniew Olczak, Katarzyna Gruszczynska and Ze’ev Hochberg

Introduction Nonsyndromic childhood obesity is associated with nonalcoholic fatty liver disease (NAFLD), a spectrum of conditions, ranging from steatosis to nonalcoholic steatohepatitis (NASH), and various degrees of fibrosis and cirrhosis ( 1

Open access

Sandrine Visentin, Gérard Michel, Claire Oudin, Béatrice Cousin, Bénédicte Gaborit, Inès Abdesselam, Marie Maraninchi, Marion Nowicki, René Valéro, Maxime Guye, Monique Bernard, Pascal Auquier, Hervé Chambost, Marie-Christine Alessi and Sophie Béliard

be protective against NAFLD (nonalcoholic fatty liver disease) ( 35 ). Similarly, we observed a significantly higher rate of liver steatosis associated with a lower BMI, and a trend toward decreased TAT and SAT after TBI in patients who had been

Open access

Min Li, Ying Chen, Jingjing Jiang, Yan Lu, Zhiyi Song, Shengjie Zhang, Chao Sun, Hao Ying, Xiaofang Fan, Yuping Song, Jialin Yang and Lin Zhao

production through the regulation of phosphoenolpyruvate carboxykinase (PEPCK) ( 32 , 33 ). In addition, recent studies have demonstrated that impaired thyroid action is associated with nonalcoholic fatty liver disease (NAFLD), and selective TH receptor

Open access

Leanne Hodson and Fredrik Karpe

perceived as prejudicing the impartiality of this review. Funding L H is a British Heart Foundation Senior Research Fellow in Basic Science. References 1 Samuel VT Shulman GI . Nonalcoholic fatty liver disease as a nexus of metabolic

Open access

Agnieszka Adamska, Aleksandra Maria Polak, Anna Krentowska, Agnieszka Łebkowska, Justyna Hryniewicka, Monika Leśniewska and Irina Kowalska

.1093/humrep/dew076 ) 6 Angulo P . Nonalcoholic fatty liver disease . New England Journal of Medicine 2002 346 . ( ) 7 Lee C Bongcam-Rudloff E Sollner C Jahnen-Dechent W Claesson-Welsh L . Type 3